Format

Send to

Choose Destination
Clin Perinatol. 2015 Sep;42(3):557-66. doi: 10.1016/j.clp.2015.04.016. Epub 2015 May 23.

Darbepoetin Administration in Term and Preterm Neonates.

Author information

1
Division of Neonatology, Department of Pediatrics, University of Utah, 296 Chipeta Way, Salt Lake City, UT 84105, USA.
2
Division of Neonatology, Department of Pediatrics, University of New Mexico, MSC10 5590, 1 University of New Mexico, Albuquerque, NM 87131-0001, USA. Electronic address: rohls@salud.unm.edu.

Abstract

Erythropoiesis-stimulating agents (ESAs) such as erythropoietin have been studied as red cell growth factors in preterm and term infants for more than 20 years. Recent studies have evaluated darbepoetin (Darbe, a long-acting ESA) for both erythropoietic effects and potential neuroprotection. We review clinical trials of Darbe in term and preterm infants, which have reported significant erythropoietic uses and neuroprotective effects. ESAs show great promise in decreasing or eliminating transfusions, and in preventing and treating brain injury in term and preterm infants.

KEYWORDS:

Anemia; Darbepoetin; Erythropoiesis-stimulating agents; Neurodevelopment; Neuroprotection; Transfusions

PMID:
26250917
PMCID:
PMC4529960
DOI:
10.1016/j.clp.2015.04.016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center